Vinod Kumar Yadav
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vinod Kumar Yadav has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Shantanu Chowdhury
Integrative and Functional Biology Unit, CSIR Institute of Genomics and Integrative Biology (IGIB), 110025, New Delhi, India
12 shared publications Ram Krishna Thakur
Proteomics and Structural Biology Unit, Institute of Genomics and Integrative Biology, CSIR, Mall Road, Delhi 110 007, India
8 shared publicationsAradhita Baral
Proteomics and Structural Biology Unit, Institute of Genomics and Integrative Biology, Council for Scientific and Industrial Research, New Delhi, India
6 shared publicationsAkinchan Kumar
Proteomics and Structural Biology Unit, Institute of Genomics and Integrative Biology, CSIR, Mall Road, Delhi 110 007, India
5 shared publicationsAnkita Singh
Proteomics and Structural Biology Unit, Institute of Genomics and Integrative Biology, CSIR, Mall Road, Delhi 110 007, India Academy of Scientific and Innovative Research (AcSIR), New Delhi, India
5 shared publications- Pankaj Kumar
Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
5 shared publications
Latest Publications
- 1 January 2019
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 39, 174-177
Does retinoic acid reverse cell cycle dysregulation in Alzheimer’s disease lymphocytes?
- 1 January 2019
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 39, 174-177
Does retinoic acid reverse cell cycle dysregulation in Alzheimer’s disease lymphocytes?
- Open Access
- 1 August 2018
- Published by Elsevier in Cancer Cell
- Vol. 34 (2) , 197-210.e5
The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations
- 1 August 2018
- Published by Elsevier in Cancer Cell
- Vol. 34 (2) , 197-210.e5
Open AccessThe Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations
- Open Access
The Tandem Duplicator Phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations
SUMMARY: The tandem duplicator phenotype (TDP) is a genome-wide instability configuration primarily observed in breast, ovarian and endometrial carcinomas. Here, we stratify TDP tumors by classifying their tandem duplications (TDs) into three span intervals, with modal values of 11 Kb, 231 Kb, and 1.7 Mb. TDPs with prominent ~11 Kb TDs feature the conjoint loss of TP53 and BRCA1 . TDPs with ~231 Kb and ~1.7 Mb TDs associate with CCNE1 pathway activation or CDK12 disruptions, in conjunction with TP53 mutations. We prove the driver role of TP53 and BRCA1 abrogation for TDP induction by generating short-span TDP mammary tumors in genetically modified mouse models harboring deleterious mutations in only these two genes. Lastly, heterogeneous combinations of mutations mediated by TDs are selected for and contribute to the oncogenic burden of TDP tumors.
Open AccessThe Tandem Duplicator Phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations
SUMMARY: The tandem duplicator phenotype (TDP) is a genome-wide instability configuration primarily observed in breast, ovarian and endometrial carcinomas. Here, we stratify TDP tumors by classifying their tandem duplications (TDs) into three span intervals, with modal values of 11 Kb, 231 Kb, and 1.7 Mb. TDPs with prominent ~11 Kb TDs feature the conjoint loss of TP53 and BRCA1 . TDPs with ~231 Kb and ~1.7 Mb TDs associate with CCNE1 pathway activation or CDK12 disruptions, in conjunction with TP53 mutations. We prove the driver role of TP53 and BRCA1 abrogation for TDP induction by generating short-span TDP mammary tumors in genetically modified mouse models harboring deleterious mutations in only these two genes. Lastly, heterogeneous combinations of mutations mediated by TDs are selected for and contribute to the oncogenic burden of TDP tumors.
- Open Access
- 1 November 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (48) , 25280
Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells.
- 1 November 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (48) , 25280
Open AccessRational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells.
- Open Access
- 8 June 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 1-9
Significance of duon mutations in cancer genomes
Functional mutations in coding regions not only affect the structure and function of the protein products, but may also modulate their expression in some cases. This class of mutations, recently dubbed “duon mutations” due to their dual roles, can potentially have major impacts on downstream pathways. However their significance in diseases such as cancer remain unclear. In a survey covering 4606 samples from 19 cancer types and integrating allelic expression, overall mRNA expression, regulatory motif perturbation and chromatin signatures in one composite index called REDACT score, we identified potential duon mutations. Several such mutations are detected in known cancer genes in multiple cancer types. For instance a potential duon mutation in TP53 is associated with increased expression of the mutant allelic gene copy, thereby possibly amplifying the functional effects on the downstream pathways. Another potential duon mutation in SF3B1 is associated with abnormal splicing and changes in angiogenesis and matrix degradation related pathways. Our findings emphasize the need to interrogate the mutations in coding regions beyond their obvious effects on protein structures.
- 8 June 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 1-9
Open AccessSignificance of duon mutations in cancer genomes
Functional mutations in coding regions not only affect the structure and function of the protein products, but may also modulate their expression in some cases. This class of mutations, recently dubbed “duon mutations” due to their dual roles, can potentially have major impacts on downstream pathways. However their significance in diseases such as cancer remain unclear. In a survey covering 4606 samples from 19 cancer types and integrating allelic expression, overall mRNA expression, regulatory motif perturbation and chromatin signatures in one composite index called REDACT score, we identified potential duon mutations. Several such mutations are detected in known cancer genes in multiple cancer types. For instance a potential duon mutation in TP53 is associated with increased expression of the mutant allelic gene copy, thereby possibly amplifying the functional effects on the downstream pathways. Another potential duon mutation in SF3B1 is associated with abnormal splicing and changes in angiogenesis and matrix degradation related pathways. Our findings emphasize the need to interrogate the mutations in coding regions beyond their obvious effects on protein structures.
- 7 April 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (17) , E2373-E2382
The tandem duplicator phenotype as a distinct genomic configuration in cancer
Significance: In this study, we provide the first detailed molecular characterization, to our knowledge, of a distinct cancer genomic configuration, the tandem duplicator phenotype (TDP), that is significantly enriched in the molecularly related triple-negative breast, serous ovarian, and endometrial carcinomas. We show here that TDP represents an oncogenic configuration featuring ( i ) genome-wide disruption of cancer genes, ( ii ) loss of cell cycle control and DNA damage repair, and ( iii ) increased sensitivity to cisplatin chemotherapy both in vitro and in vivo. Therefore, the TDP is a systems strategy to achieve a protumorigenic genomic configuration by altering a large number of oncogenes and tumor suppressors. The TDP arises in a molecular context of joint genomic instability and replicative drive, and is consequently associated with enhanced sensitivity to cisplatin.
- 7 April 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (17) , E2373-E2382
The tandem duplicator phenotype as a distinct genomic configuration in cancer
Significance: In this study, we provide the first detailed molecular characterization, to our knowledge, of a distinct cancer genomic configuration, the tandem duplicator phenotype (TDP), that is significantly enriched in the molecularly related triple-negative breast, serous ovarian, and endometrial carcinomas. We show here that TDP represents an oncogenic configuration featuring ( i ) genome-wide disruption of cancer genes, ( ii ) loss of cell cycle control and DNA damage repair, and ( iii ) increased sensitivity to cisplatin chemotherapy both in vitro and in vivo. Therefore, the TDP is a systems strategy to achieve a protumorigenic genomic configuration by altering a large number of oncogenes and tumor suppressors. The TDP arises in a molecular context of joint genomic instability and replicative drive, and is consequently associated with enhanced sensitivity to cisplatin.
- Open Access
- 28 March 2016
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 23 (4) , 721-730
IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples
Objective Currently, there is a disconnect between finding a patient’s relevant molecular profile and predicting actionable therapeutics. Here we develop and implement the Integrating Molecular Profiles with Actionable Therapeutics (IMPACT) analysis pipeline, linking variants detected from whole-exome sequencing (WES) to actionable therapeutics. Methods and materials The IMPACT pipeline contains 4 analytical modules: detecting somatic variants, calling copy number alterations, predicting drugs against deleterious variants, and analyzing tumor heterogeneity. We tested the IMPACT pipeline on whole-exome sequencing data in The Cancer Genome Atlas (TCGA) lung adenocarcinoma samples with known EGFR mutations. We also used IMPACT to analyze melanoma patient tumor samples before treatment, after BRAF-inhibitor treatment, and after BRAF- and MEK-inhibitor treatment. Results IMPACT Food and Drug Administration (FDA) correctly identified known EGFR mutations in the TCGA lung adenocarcinoma samples. IMPACT linked these EGFR mutations to the appropriate FDA-approved EGFR inhibitors. For the melanoma patient samples, we identified NRAS p.Q61K as an acquired resistance mutation to BRAF-inhibitor treatment. We also identified CDKN2A deletion as a novel acquired resistance mutation to BRAFi/MEKi inhibition. The IMPACT analysis pipeline predicts these somatic variants to actionable therapeutics. We observed the clonal dynamic in the tumor samples after various treatments. We showed that IMPACT not only helped in successful prioritization of clinically relevant variants but also linked these variations to possible targeted therapies. Conclusion IMPACT provides a new bioinformatics strategy to delineate candidate somatic variants and actionable therapies. This approach can be applied to other patient tumor samples to discover effective drug targets for personalized medicine. IMPACT is publicly available at http://tanlab.ucdenver.edu/IMPACT.
- 28 March 2016
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 23 (4) , 721-730
Open AccessIMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples
Objective Currently, there is a disconnect between finding a patient’s relevant molecular profile and predicting actionable therapeutics. Here we develop and implement the Integrating Molecular Profiles with Actionable Therapeutics (IMPACT) analysis pipeline, linking variants detected from whole-exome sequencing (WES) to actionable therapeutics. Methods and materials The IMPACT pipeline contains 4 analytical modules: detecting somatic variants, calling copy number alterations, predicting drugs against deleterious variants, and analyzing tumor heterogeneity. We tested the IMPACT pipeline on whole-exome sequencing data in The Cancer Genome Atlas (TCGA) lung adenocarcinoma samples with known EGFR mutations. We also used IMPACT to analyze melanoma patient tumor samples before treatment, after BRAF-inhibitor treatment, and after BRAF- and MEK-inhibitor treatment. Results IMPACT Food and Drug Administration (FDA) correctly identified known EGFR mutations in the TCGA lung adenocarcinoma samples. IMPACT linked these EGFR mutations to the appropriate FDA-approved EGFR inhibitors. For the melanoma patient samples, we identified NRAS p.Q61K as an acquired resistance mutation to BRAF-inhibitor treatment. We also identified CDKN2A deletion as a novel acquired resistance mutation to BRAFi/MEKi inhibition. The IMPACT analysis pipeline predicts these somatic variants to actionable therapeutics. We observed the clonal dynamic in the tumor samples after various treatments. We showed that IMPACT not only helped in successful prioritization of clinically relevant variants but also linked these variations to possible targeted therapies. Conclusion IMPACT provides a new bioinformatics strategy to delineate candidate somatic variants and actionable therapies. This approach can be applied to other patient tumor samples to discover effective drug targets for personalized medicine. IMPACT is publicly available at http://tanlab.ucdenver.edu/IMPACT.
- 15 March 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 196 (6) , 2847-2859
Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer
Macrophages represent an important component of the tumor microenvironment and play a complex role in cancer progression. These cells are characterized by a high degree of plasticity, and they alter their phenotype in response to local environmental cues. Whereas the M1/M2 classification of macrophages has been widely used, the complexity of macrophage phenotypes has not been well studied, particularly in lung cancer. In this study we employed an orthotopic immunocompetent model of lung adenocarcinoma in which murine lung cancer cells are directly implanted into the left lobe of syngeneic mice. Using multimarker flow cytometry, we defined and recovered several distinct populations of monocytes/macrophages from tumors at different stages of progression. We used RNA-seq transcriptional profiling to define distinct features of each population and determine how they change during tumor progression. We defined an alveolar resident macrophage population that does not change in number and expresses multiple genes related to lipid metabolism and lipid signaling. We also defined a population of tumor-associated macrophages that increase dramatically with tumor and selectively expresses a panel of chemokine genes. A third population, which resembles tumor-associated monocytes, expresses a large number of genes involved in matrix remodeling. By correlating transcriptional profiles with clinically prognostic genes, we show that specific monocyte/macrophage populations are enriched in genes that predict outcomes in lung adenocarcinoma, implicating these subpopulations as critical determinants of patient survival. Our data underscore the complexity of monocytes/macrophages in the tumor microenvironment, and they suggest that distinct populations play specific roles in tumor progression.
- 15 March 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 196 (6) , 2847-2859
Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer
Macrophages represent an important component of the tumor microenvironment and play a complex role in cancer progression. These cells are characterized by a high degree of plasticity, and they alter their phenotype in response to local environmental cues. Whereas the M1/M2 classification of macrophages has been widely used, the complexity of macrophage phenotypes has not been well studied, particularly in lung cancer. In this study we employed an orthotopic immunocompetent model of lung adenocarcinoma in which murine lung cancer cells are directly implanted into the left lobe of syngeneic mice. Using multimarker flow cytometry, we defined and recovered several distinct populations of monocytes/macrophages from tumors at different stages of progression. We used RNA-seq transcriptional profiling to define distinct features of each population and determine how they change during tumor progression. We defined an alveolar resident macrophage population that does not change in number and expresses multiple genes related to lipid metabolism and lipid signaling. We also defined a population of tumor-associated macrophages that increase dramatically with tumor and selectively expresses a panel of chemokine genes. A third population, which resembles tumor-associated monocytes, expresses a large number of genes involved in matrix remodeling. By correlating transcriptional profiles with clinically prognostic genes, we show that specific monocyte/macrophage populations are enriched in genes that predict outcomes in lung adenocarcinoma, implicating these subpopulations as critical determinants of patient survival. Our data underscore the complexity of monocytes/macrophages in the tumor microenvironment, and they suggest that distinct populations play specific roles in tumor progression.
- Open Access
- 15 February 2016
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 44 (5) , 2075-84
The landscape of somatic mutations in protein coding genes in apparently benign human tissues carries signatures of relaxed purifying selection.
Mutations acquired during development and aging lead to inter- and intra-tissue genetic variations. Evidence linking such mutations to complex traits and diseases is rising. We detected somatic mutations in protein-coding regions in 140 benign tissue samples representing nine tissue-types (bladder, breast, liver, lung, prostate, stomach, thyroid, head and neck) and paired blood from 70 donors. A total of 80% of the samples had 2-39 mutations detectable at tissue-level resolution. Factors such as age and smoking were associated with increased burden of detectable mutations, and tissues carried signatures of distinct mutagenic processes such as oxidative DNA damage and transcription-coupled repair. Using mutational signatures, we predicted that majority of the mutations in blood originated in hematopoietic stem and early progenitor cells. Missense to silent mutations ratio and the persistence of potentially damaging mutations in expressed genes carried signatures of relaxed purifying selection. Our findings have relevance for etiology, diagnosis and treatment of diseases including cancer.
- 15 February 2016
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 44 (5) , 2075-84
Open AccessThe landscape of somatic mutations in protein coding genes in apparently benign human tissues carries signatures of relaxed purifying selection.
Mutations acquired during development and aging lead to inter- and intra-tissue genetic variations. Evidence linking such mutations to complex traits and diseases is rising. We detected somatic mutations in protein-coding regions in 140 benign tissue samples representing nine tissue-types (bladder, breast, liver, lung, prostate, stomach, thyroid, head and neck) and paired blood from 70 donors. A total of 80% of the samples had 2-39 mutations detectable at tissue-level resolution. Factors such as age and smoking were associated with increased burden of detectable mutations, and tissues carried signatures of distinct mutagenic processes such as oxidative DNA damage and transcription-coupled repair. Using mutational signatures, we predicted that majority of the mutations in blood originated in hematopoietic stem and early progenitor cells. Missense to silent mutations ratio and the persistence of potentially damaging mutations in expressed genes carried signatures of relaxed purifying selection. Our findings have relevance for etiology, diagnosis and treatment of diseases including cancer.
- 20 November 2015
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 32 (6) , 808-813
SomVarIUS: somatic variant identification from unpaired tissue samples
Motivation: Somatic variant calling typically requires paired tumornormal tissue samples. Yet, paired normal tissues are not always available in clinical settings or for archival samples
- 20 November 2015
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 32 (6) , 808-813
SomVarIUS: somatic variant identification from unpaired tissue samples
Motivation: Somatic variant calling typically requires paired tumornormal tissue samples. Yet, paired normal tissues are not always available in clinical settings or for archival samples